Amgen delivered strong quarterly results with significant revenue and earnings growth, raised its guidance, and showcased a robust pipeline with new product launches. While there are challenges from biosimilar competition and increased tax rates, the overall outlook remains positive, supported by increased dividends and share buybacks. These factors are likely to bolster investor confidence in the short term.

[1]